Search results for "Protein-Tyrosine Kinases"

showing 10 items of 122 documents

Ten new cases further delineate the syndromic intellectual disability phenotype caused by mutations in DYRK1A.

2015

The dual-specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) gene, located on chromosome 21q22.13 within the Down syndrome critical region, has been implicated in syndromic intellectual disability associated with Down syndrome and autism. DYRK1A has a critical role in brain growth and development primarily by regulating cell proliferation, neurogenesis, neuronal plasticity and survival. Several patients have been reported with chromosome 21 aberrations such as partial monosomy, involving multiple genes including DYRK1A. In addition, seven other individuals have been described with chromosomal rearrangements, intragenic deletions or truncating mutations that disrupt specificall…

AdultMaleMicrocephalyMonosomyDown syndromeAdolescentChromosomes Human Pair 21BiologyProtein Serine-Threonine KinasesArticleIntellectual DisabilityIntellectual disabilityGeneticsmedicineHumansAutistic DisorderChildGenetics (clinical)Chromosomal DeletionGeneticsProtein-Tyrosine Kinasesmedicine.diseasePhenotypeChild PreschoolSpeech delayMutationMicrocephalyAutismFemalemedicine.symptomChromosome DeletionDown SyndromeChromosome 21European journal of human genetics : EJHG
researchProduct

Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral b…

2001

We examined safety and efficacy of STI-571 in 24 bcr/abl-positive patients with CML post PBSCT. At start of STI-571 therapy, nine patients presented in blast crisis (BC) or in accelerated phase (AP), and 15 in chronic phase (CP). Patients were evaluated for hematologic, cytogenetic and molecular response, survival and toxicity. In general, STI-571 was well tolerated in this heavily pretreated group of patients with a non-hematologic and hematologic toxicity profile similar to that observed in a previous phase I trial at comparable doses. Five of nine patients with CML in transformation (AP, BC) were evaluable for hematologic response. Two of five patients had transient reductions in WBC and…

AdultMaleOncologyCancer Researchmedicine.medical_specialtymedicine.medical_treatmentFusion Proteins bcr-ablAntineoplastic AgentsPhiladelphia chromosomeTransplantation AutologousPiperazinesLeukemia Myelogenous Chronic BCR-ABL Positivehemic and lymphatic diseasesInternal medicinemedicineHumansEnzyme InhibitorsChemotherapyABLbusiness.industryHematopoietic Stem Cell Transplantationbreakpoint cluster regionHematologyMiddle AgedProtein-Tyrosine Kinasesmedicine.diseaseCombined Modality TherapyHematologic ResponseBlood Cell CountPyrimidinesTreatment OutcomeImatinib mesylateOncologyBenzamidesToxicityImmunologyImatinib MesylateFemaleComplicationbusinessLeukemia
researchProduct

Novel rearrangements involving the RET gene in papillary thyroid carcinoma.

2018

Abstract Background In the field of gene fusions driving tumorigenesis in papillary thyroid carcinoma (PTC), rearrangement of the proto-oncogene RET is the most frequent alteration. Apart from the most common rearrangement of RET to CCDC6, more than 15 partner genes are yet reported. The landscape of RET rearrangements in PTC (“RET-PTC”) can notably be enlarged by modern targeted next-generation sequencing, indicating similarities between oncogenic pathways in other cancer types with identical genetic alterations. Methods Targeted next-generation sequencing was performed for two cases of BRAF-wild type PTC with confirmation of the results by Sanger sequencing. A “UniProt” database research …

AdultMalecongenital hereditary and neonatal diseases and abnormalitiesendocrine systemCancer Researchendocrine system diseasesOncogene Proteins FusionBiologyRUN domainmedicine.disease_causeProto-Oncogene MasFusion gene03 medical and health sciencessymbols.namesake0302 clinical medicineGeneticsmedicineHumansThyroid NeoplasmsneoplasmsMolecular BiologyGeneSanger sequencingGene RearrangementProto-Oncogene Proteins c-retIntracellular Signaling Peptides and ProteinsCancerHigh-Throughput Nucleotide SequencingNuclear ProteinsProtein-Tyrosine Kinasesmedicine.diseaseLisH domainThyroid Cancer Papillary030220 oncology & carcinogenesisCancer researchsymbolsFemaleCarcinogenesisCarrier ProteinsTyrosine kinaseCancer genetics
researchProduct

Sustained Complete Molecular Remissions After Treatment With Imatinib-Mesylate in Patients With Failure After Allogeneic Stem Cell Transplantation fo…

2005

Purpose In the era of molecular therapy of chronic myelogenous leukemia (CML) applying BCR-ABL tyrosine kinase inhibitors, the usefulness of molecular end points, in particular, quantitative polymerase chain reaction (PCR) for BCR-ABL in monitoring responses has been broadly accepted. Therefore, we have designed a prospective phase II trial in CML, which, for the first time, evaluated the feasibility and safety of molecular end points as surrogate markers to guide through a stratified treatment algorithm within a multicenter trial. Patients and Methods As a clinical model, we adopted minimal residual disease (MRD) found in relapse after allogeneic stem cell transplantation (SCT) in CML. For…

AdultOncologyCancer Researchmedicine.medical_specialtyTime FactorsMaximum Tolerated Dosemedicine.drug_classFusion Proteins bcr-ablGraft vs Host DiseaseAntineoplastic AgentsPolymerase Chain ReactionPiperazinesTyrosine-kinase inhibitorMyelogenousLeukemia Myelogenous Chronic BCR-ABL Positivehemic and lymphatic diseasesMulticenter trialInternal medicinemedicineHumansTransplantation HomologousProspective Studiesbusiness.industryRemission InductionImatinibProtein-Tyrosine Kinasesmedicine.diseaseMinimal residual diseaseTransplantationPyrimidinesTreatment OutcomeImatinib mesylateOncologyBenzamidesImmunologyImatinib MesylateFeasibility StudiesbusinessStem Cell Transplantationmedicine.drugChronic myelogenous leukemiaJournal of Clinical Oncology
researchProduct

A role for the MAP kinase gene MKC1 in cell wall construction and morphological transitions in Candida albicans.

1998

The Candida albicans MKC1 gene encodes a mitogen-activated protein (MAP) kinase, which has been cloned by complementation of the lytic phenotype associated with Saccharomyces cerevisiae slt2 (mpk1) mutants. In this work, the physiological role of this MAP kinase in the pathogenic fungus C. albicans was characterized and a role for MKC1 in the biogenesis of the cell wall suggested based on the following criteria. First, C. albicans mkc1Δ/mkc1Δ strains displayed alterations in their cell surfaces under specific conditions as evidenced by scanning electron microscopy. Second, an increase in specific cell wall epitopes (O-glycosylated mannoprotein) was shown by confocal microscopy in mkc1Δ/mkc1…

Antifungal AgentsTranscription GeneticSaccharomyces cerevisiaeMutantMAP Kinase Kinase 2MAP Kinase Kinase 1ChitinSaccharomyces cerevisiaeProtein Serine-Threonine KinasesMicrobiologyGene Expression Regulation EnzymologicFungal ProteinsPseudohyphal growthCell WallGene Expression Regulation FungalCandida albicansCandida albicansDNA FungalFluorescent Antibody Technique IndirectGlucansProtein Kinase CMitogen-Activated Protein Kinase KinasesRecombination GeneticMembrane GlycoproteinsMicroscopy ConfocalbiologyKinaseProtein-Tyrosine Kinasesbiology.organism_classificationFlow Cytometrybeta-GalactosidaseCorpus albicansComplementationMicroscopy ElectronBiochemistryMitogen-activated protein kinaseCalcium-Calmodulin-Dependent Protein Kinasesbiology.proteinMicroscopy Electron ScanningMitogen-Activated Protein KinasesPlasmidsMicrobiology (Reading, England)
researchProduct

Structure-activity relationship of staurosporine analogs in regulating expression of endothelial nitric-oxide synthase gene.

2000

In human umbilical vein endothelial cells and in human umbilical vein endothelial cell-derived EA.hy 926 cells, staurosporine (Stsp) and its glycosidic indolocarbazole analogs 7-hydroxystaurosporine (UCN-01) and 4'-N-benzoyl staurosporine (CGP 41251) enhanced nitric-oxide synthase (NOS) III mRNA expression (analyzed by RNase protection assay), protein expression (determined by Western blot), and activity [measured by rat fetal lung fibroblast (RFL-6) reporter cell assay] in a concentration- and time-dependent manner. In contrast, the bisindolylmaleimide analogs GF 109203X, Ro 31-8220 and Go 6983 had no effect on NOS III expression, and Go 6976, a methyl- and cyanoalkyl-substituted nonglycos…

BisindolylmaleimideNitric Oxide Synthase Type IIIBiologyEndothelial NOSNitric OxideGene Expression Regulation Enzymologicchemistry.chemical_compoundStructure-Activity RelationshipAlkaloidsmedicineCyclic GMP-Dependent Protein KinasesStaurosporineAnimalsHumansDrug InteractionsRNA MessengerEnzyme InhibitorsProtein kinase APromoter Regions GeneticProtein Kinase InhibitorsProtein kinase CCells CulturedProtein Kinase CPharmacologyKinaseTumor Necrosis Factor-alphaNitric Oxide Synthase Type IIIProtein-Tyrosine KinasesStaurosporineMolecular biologyCyclic AMP-Dependent Protein KinasesRatschemistryMolecular MedicineEndothelium VascularNitric Oxide SynthaseTyrosine kinaseProtein Kinasesmedicine.drugMolecular pharmacology
researchProduct

ENDOCRINE SIDE EFFECTS OF ANTI-CANCER DRUGS: Effects of anti-cancer targeted therapies on lipid and glucose metabolism

2014

During the past years, targeted therapies for cancer have been developed using drugs that have significant metabolic consequences. Among them, the mammalian target of rapamycin (mTOR) inhibitors and, to a much lesser extent, the tyrosine kinase inhibitors (TKIs) are involved. mTOR plays a key role in the regulation of cell growth as well as lipid and glucose metabolism. Treatment with mTOR inhibitors is associated with a significant increase in plasma triglycerides and LDL cholesterol. mTOR inhibitors seem to increase plasma triglycerides by reducing the activity of the lipoprotein lipase which is in charge of the catabolism of triglyceride-rich lipoproteins. The increase in LDL cholesterol…

Blood Glucosemedicine.medical_specialtyEndocrinology Diabetes and MetabolismAntineoplastic AgentsHypoglycemiaCarbohydrate metabolismBiologyEndocrinologyInsulin resistanceInternal medicineHyperlipidemiamedicineHomeostasisHumansGlucose homeostasisEnzyme InhibitorsTriglyceridesPI3K/AKT/mTOR pathwayLipoprotein lipaseTOR Serine-Threonine KinasesGeneral MedicineProtein-Tyrosine KinasesLipid Metabolismmedicine.diseaseEndocrinologyLDL receptorCarbohydrate MetabolismEuropean Journal of Endocrinology
researchProduct

The Serine/Threonine Protein Phosphatase 2A (PP2A) Regulates Syk Activity in Human Platelets

2020

Distinct membrane receptors activate platelets by Src-family-kinase (SFK)-, immunoreceptor-tyrosine-based-activation-motif (ITAM)-dependent stimulation of spleen tyrosine kinase (Syk). Recently, we reported that platelet activation via glycoprotein (GP) VI or GPIb&alpha

Blood Platelets0301 basic medicinePlatelet AggregationPhosphataseSykchemical and pharmacologic phenomena030204 cardiovascular system & hematologyenvironment and public healthspleen tyrosine kinase (Syk)ArticleCatalysisInorganic ChemistryDephosphorylationglycoprotein VIglycoprotein Ibα03 medical and health sciences0302 clinical medicineHumansSyk KinaseProtein Phosphatase 2Platelet activationPhosphorylationPhysical and Theoretical ChemistryMolecular BiologySpectroscopyProtein kinase CChemistryKinaseprotein phosphatase 2AOrganic Chemistryhemic and immune systemsGeneral MedicineProtein phosphatase 2Protein-Tyrosine KinasesPlatelet Activation3. Good healthComputer Science ApplicationsCell biologyenzymes and coenzymes (carbohydrates)030104 developmental biologyplateletsPhosphorylationbiological phenomena cell phenomena and immunitySignal TransductionInternational Journal of Molecular Sciences
researchProduct

Reduced T-cell receptor CD3ζ-chain protein and sustained CD3ε expression at the site of mycobacterial infection

2001

Control of mycobacterial infection by the cellular immune system relies both on antigen-presenting cells and on T lymphocytes. The quality of an effective cellular immune response is dependent on functional signal transduction residing in the cytoplasmic tails of the T-cell receptor CD3 components. In order to investigate potential effects of mycobacteria on T-cell receptor signalling, we examined the protein expression of T-cell signal transduction molecules (CD3zeta, ZAP-70, p59fyn, p56lck). In Western blots of peripheral blood mononuclear cells of Mycobacterium tuberculosis infected patients, only the CD3zeta-chain showed a marked reduction in protein expression. To investigate the situa…

CD3 ComplexCD3ImmunologyPalatine TonsilReceptors Antigen T-CellFluorescent Antibody TechniqueImmunofluorescenceProto-Oncogene Proteins c-fynPeripheral blood mononuclear cellImmunoenzyme TechniquesImmune systemSarcoidosis PulmonaryProto-Oncogene ProteinsmedicineImmunology and AllergyHumansReceptorTuberculosis PulmonaryMycobacterium InfectionsGranulomaZAP-70 Protein-Tyrosine Kinasemedicine.diagnostic_testbiologyT-cell receptorMembrane ProteinsOriginal ArticlesProtein-Tyrosine KinasesMolecular biologyLeprosy LepromatousLymphatic systemLymphocyte Specific Protein Tyrosine Kinase p56(lck)Immunologybiology.proteinInterleukin-2Signal transductionSignal Transduction
researchProduct

Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological c…

2022

Abstract Background The survival of patients with lung cancer has substantially increased in the last decade by about 15%. This increase is, basically, due to targeted therapies available for advanced stages and the emergence of immunotherapy itself. This work aims to study the situation of biomarker testing in Spain. Patients and methods The Thoracic Tumours Registry (TTR) is an observational, prospective, registry-based study that included patients diagnosed with lung cancer and other thoracic tumours, from September 2016 to 2020. This TTR study was sponsored by the Spanish Lung Cancer Group (GECP) Foundation, an independent, scientific, multidisciplinary oncology society that coordinates…

Cancer Research:Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms [DISEASES]Lung NeoplasmsTesting:Biological Factors::Biomarkers [CHEMICALS AND DRUGS]:factores biológicos::biomarcadores [COMPUESTOS QUÍMICOS Y DROGAS]Targeted therapiesPulmons - Càncer:neoplasias::neoplasias por localización::neoplasias torácicas::neoplasias del tracto respiratorio::neoplasias pulmonares [ENFERMEDADES]Carcinoma Non-Small-Cell LungProto-Oncogene ProteinsGeneticsBiomarkers TumorHumansProspective StudiesCàncerDemographyReceptor Protein-Tyrosine KinasesProtein-Tyrosine KinasesErbB ReceptorsOncologySpainPulmonsMarcadors bioquímicsBiomarkersMetastatic lung cancer
researchProduct